Automated and Closed Cell Therapy Market - Strategic Insights and Forecasts (2026-2031)

The Automated and Closed Cell Therapy market is set to reach USD 4,236.0 million in 2031, growing at a CAGR of 14.2% between 2026 and 2031, from USD 2,179.3 million in 2026.

Key Highlights

Market Overview

The Automated and Closed Cell Therapy Market covers integrated, self-contained platforms, including apheresis, cell separation, activation, expansion, and cryopreservation, which manufacture CAR-T and other cell therapies with minimal manual handling. As cell therapies move from clinical to commercial-scale production, closed and automated systems are increasingly displacing manual, open-processing workflows.

• The FDA has moved to embed cell therapy manufacturers into pre-approval regulatory planning rather than reviewing readiness only at inspection. Its new PreCheck Pilot Program lets participants receive early technical guidance before a facility becomes operational, including review of facility information submitted through a facility-specific Drug Master File.

• Cellares was the only cell-based gene therapy company selected into this inaugural cohort. Participation gives Cellares access to facility-specific DMF reviews, Pre-Operational Reviews, Pre-Submission Evaluations of GMP facilities, and structured dialogue on facility design, quality systems, and manufacturing processes.

• The FDA has also begun granting technology-specific manufacturing designations. Cellares' Cell Shuttle is the first cell therapy manufacturing platform to receive the FDA's Advanced Manufacturing Technology (AMT) designation, and Lonza's competing platform has since followed. Lonza's Cocoon Platform received Advanced Manufacturing Technologies (AMT) Designation from the FDA in December 2025.

• In the EU, the regulatory center of gravity for cell therapies is shifting structurally. In December 2025, the EU agreed on a major reform of its pharmaceutical legislation, proposing to streamline EMA's governance by integrating the Committee for Advanced Therapies (CAT) into the Committee for Medicinal Products for Human Use (CHMP).

• The EMA frames this as part of a broader legislative overhaul. The new pharmaceutical legislation represents the most significant overhaul of the EU regulatory framework in over two decades, covering medicines for human use across development, authorisation, and safety monitoring. EMA says that the adopted acts are expected to enter into force in 2026, followed by a transition period through 2028 for member states to align national law.

• Suppliers continue to expand closed-system manufacturing capacity on the ground. Lonza's CDMO network spans manufacturing sites in Portsmouth (NH), Houston (TX), Geleen (Netherlands), Siena (Italy), and Singapore, supporting both allogeneic and autologous cell therapy production.

Key Market Indicators

Key indicator: Cell therapies remain among the most manufacturing-intensive products in biopharmaceutical production.

Commercial meaning: Manufacturing efficiency increasingly influences therapy accessibility, reimbursement discussions, and commercial viability.

Market Drivers

Commercialization of Advanced Cell Therapies

Regulatory bodies and manufacturers across major markets are tracking a steady expansion in the number of licensed cell and gene therapies moving into routine clinical use, even as growth varies sharply by therapy class. This commercialization wave is a key factor driving the Automated and Closed Cell Therapy market. Sponsors require closed, automated platforms to manufacture living-cell products with the necessary batch volume, consistency, and turnaround time required to meet the needs of a growing, geographically dispersed patient population. Without these capabilities, approved therapies cannot be delivered to patients at scale.

• The FDA's official registry shows the products requiring commercial-scale manufacturing infrastructure. FDA's Office of Therapeutic Products lists dozens of licensed cellular and gene therapy products as of July 2026, spanning CAR-T therapies (Yescarta, Kymriah, Carvykti, Breyanzi, Abecma, Tecartus, Aucatzyl), cord-blood and stem-cell products, and an expanding slate of gene therapies, each requiring dedicated closed-processing capacity to move from clinical trial to routine supply.

• Manufacturers are responding to this commercial demand by expanding physical production capacity, not just clinical output. Kite, a Gilead Company, is expanding its cell therapy manufacturing operations in Maryland, with plans to grow its workforce to over 500 full-time staff across its sites by the end of 2026. The company aims to establish what it refers to as the largest in-house cell therapy manufacturing network in the world. This network will cover all aspects of the process, including process development, vector manufacturing, clinical trial production, and commercial product manufacturing.

• Commercial-scale manufacturers are also compressing production timelines to keep pace with patient demand. The FDA approved a manufacturing process change for Kite's Yescarta that shortened CAR-T cell manufacturing time from an average of seven days to five days, which reduced the median turnaround from cell collection to product release from 16 days to 14 days.

• Regulators are streamlining pathways to keep approval and manufacturing scale-up in step. The FDA's PreCheck Pilot Program gives select sponsors, including cell and gene therapy manufacturers, early technical guidance on facility readiness before a product application is even filed, reflecting an official push to remove manufacturing bottlenecks as more therapies approach commercial launch.

• In the EU, the regulatory pipeline continues to advance new approvals through the centralized ATMP framework. In April 2026, the EMA's Committee for Advanced Therapies adopted a positive draft opinion for Itvisma (onasemnogene abeparvovec), intended for spinal muscular atrophy in patients two years of age and older, underscoring the continuing flow of new advanced-therapy approvals feeding demand for closed, GMP-compliant manufacturing platforms across the region.

Pressure to reduce manufacturing variability. Process inconsistency remains one of the most closely monitored risks in cell therapy production. Variability can arise from operator handling, environmental exposure, equipment differences, and process deviations. Automated closed systems reduce manual touchpoints and support standardized workflows, making them attractive to developers seeking predictable manufacturing outcomes across multiple production sites.

Regulatory focus on process control and data integrity. Regulatory agencies increasingly evaluate manufacturing controls alongside clinical performance. Process traceability, electronic records, environmental monitoring, and batch reproducibility have become important components of regulatory review. Automated platforms provide integrated process documentation and digital tracking capabilities that help manufacturers satisfy evolving compliance requirements.

Expansion of allogeneic cell therapy development programs. Unlike autologous therapies, allogeneic products aim to serve larger patient populations from centralized manufacturing operations. This approach requires scalable production systems capable of processing larger cell volumes while maintaining product consistency. Equipment suppliers are responding through investments in automated bioreactor technologies, integrated cell-processing platforms, and advanced monitoring systems.

Manufacturing labor constraints. Cell therapy production requires specialized personnel trained in aseptic processing, quality systems, and advanced biologics manufacturing. Several industry participants have identified workforce availability as a challenge for facility expansion. Automation reduces dependence on highly specialized operators and allows facilities to increase throughput without proportional increases in staffing levels.

Market Restraints and Challenges

High capital requirements for the manufacturing transition. Moving from manual or semi-manual workflows to fully automated closed manufacturing often requires substantial investment in equipment, facility redesign, software infrastructure, process validation, and workforce training. Smaller biotechnology companies may struggle to justify these expenditures before achieving commercial revenue or securing long-term manufacturing demand.

Limited process standardization across therapies. Cell therapies differ considerably in cell source, expansion methods, processing requirements, and quality specifications. A manufacturing platform optimized for one therapy may require significant modification for another. This limits the degree of standardization achievable across the industry and increases implementation complexity for equipment suppliers.

Lengthy validation and qualification cycles. Cell therapy manufacturers operate within highly regulated environments where equipment changes can trigger extensive qualification activities. Introducing automated platforms often requires process comparability studies, documentation updates, and regulatory engagement. These requirements can extend implementation timelines and delay anticipated productivity benefits.

Supply-chain dependence for specialized consumables. Closed manufacturing systems frequently depend on proprietary tubing sets, single-use assemblies, reagents, sensors, and disposable components. Disruptions affecting these specialized inputs can reduce manufacturing flexibility and create operational risks. Several bioprocessing suppliers have expanded production capacity and supplier diversification efforts in response to these concerns.

Economic uncertainty around large-scale deployment. Although automation can improve efficiency, economic benefits vary according to therapy type, patient volume, reimbursement environment, and manufacturing model. Developers operating in small patient populations may find that automation delivers lower financial returns than expected, particularly when capital costs remain high relative to production volumes. Major Seg

Major Segment Analysis

Oncology

By application, the automated and closed cell therapy market is segmented into oncology, regenerative medicine, immunological disorders, cardiovascular diseases, neurological disorders, and others. Oncology is expected to show considerable growth fueled by continued investment to bolster cancer treatment.

Regulatory approvals for cell therapies, followed by ongoing technological advancements, have supported the transition towards automated solutions from manual intervention. The oncology segment is projected to grow at a steady rate, fueled by the ongoing developments to meet the commercial need for CAR-T and other cell therapies.

• Oncology, being a persistent public health challenge, has created an urge to advance treatment and therapies globally, which has simultaneously impacted its R&D spending. Research studies published by IQVIA indicate oncology accounted for 38% of global clinical trials (Phase 1-3) in 2025. Such a high share promotes adoption of automated closed cell systems for higher throughput.

• With a global annual cancer prevalence of 20.6 million, the transition towards clinical trial systems offering AI & ML compliance is especially expected to improve market expansion. WHO predicts global annual prevalence to grow to 35 million by 2050.

• Continued growth in clinical trials of novel modalities, which constitute nearly 33% of all oncology trials, has supported market development, and a regulatory shift in global economies, stimulating next-generation cell therapy development has shaped the market outlook.

• Strategic collaboration of IDMOs like Celllares with Tscan Therapeutics to automate the latter’s TCR-Therapy candidate for treating patients with acute myeloid leukemia (AML) has provided new growth prospects. Likewise, companies like Oribiotech, Ltd., through an MoU, have promoted the adoption of its automated cell therapy platform IRO for clinical researchers in Asia Pacific and Australia.

• Research partnerships with global clinical institutions followed by private investment and supply partnerships are being implemented, which have improved the market scalability for an automated closed system for oncology research & development activities.

Commercial Scale

Commercial-scale manufacturing represents the most strategically important segment of the automated and closed cell therapy market because it directly influences the ability of approved therapies to reach larger patient populations. Clinical-stage manufacturing often prioritizes flexibility and process experimentation, whereas commercial operations require validated processes, controlled costs, consistent quality outcomes, and dependable supply chains. These requirements align closely with the capabilities offered by automated closed manufacturing platforms.

Purchasing criteria within this segment differ substantially from those observed in research environments. Commercial operators prioritize batch reproducibility, facility throughput, regulatory readiness, digital integration, and long-term operating economics. Equipment performance remains important, but buyers increasingly evaluate complete manufacturing ecosystems that combine hardware, consumables, software, process analytics, and service support.

Competition within the commercial-scale segment is increasingly focused on platform integration. Suppliers are developing end-to-end manufacturing solutions that reduce handoffs between processing steps and simplify technology transfer activities. This trend favors vendors capable of supporting process development, scale-up, validation, and commercial deployment through a unified technology platform. As additional therapies progress toward commercial launch, demand for scalable manufacturing infrastructure is expected to remain concentrated within this segment.

Regional Analysis

North America

The United States remains the largest center for cell therapy development, clinical commercialization, and advanced manufacturing deployment. FDA approvals, extensive biotechnology investment, established CDMO networks, and strong venture funding activity support continued demand for automated manufacturing technologies. Suppliers frequently prioritize North American launches because many commercial manufacturing facilities are located within the region.

• The technological maturity of the United States provides an operational advantage to researchers. With billions invested in clinical R&D operations, the adoption of automated closed systems for cell therapies is expected to increase in the country.

• Strategic investments raised by companies such as Cellares and Aspen Neuroscience to integrate cutting-edge automation have improved the market landscape in the US. Likewise, ongoing biotech venture deals will further support the adoption trend.

• Implementation of policies such as the “21^st Century Cures Act” by the Food and Drug Administration has supported RMAT (Regenerative Medicine Advanced Therapy) development, which is expected to benefit the development of therapies relying on robust automated systems.

• The high prevalence of chronic disease in the US, particularly cardiovascular and oncological conditions, which account for a substantial proportion of overall disease burden and mortality, is expected to drive the articulation of CMC flexibilities for cell therapies in the country.

• Initiatives such as FDA’s “PreCheck Pilot Program” have strengthened US domestic cell culture biomanufacturing and will provide more predictable pathways that align with the ongoing automation trend.

• Progression in novel active substance (NAS) launch, which holds high applicability for automated closed cell therapy systems, has amplified the market scope. Research studies from IQVIA show that of the 75 NAS launched globally, 53 were launched in the USA.

  Report Metric	Details
  Total Market Size in 2026	USD 2,179.3 million
  Total Market Size in 2031	USD 4,236.0 million
  Forecast Unit	USD Million
  Growth Rate	14.2%
  Study Period	2021 to 2031
  Historical Data	2021 to 2024
  Base Year	2025
  Forecast Period	2026 – 2031
  Segmentation	Therapy Type, Automation Level, Scale, Application, End-User, Geography
  Companies	Miltenyi Biotec Lonza Fresenius Kabi Danaher Corporation BioSpherix

Europe

European demand is supported by advanced therapy medicinal product (ATMP) regulations, established academic research networks, and growing commercial manufacturing investments. Germany, the United Kingdom, France, and several Nordic countries continue to attract cell therapy development programs. Regulatory harmonization provides advantages, although reimbursement decisions remain fragmented across national healthcare systems.

Asia Pacific

China, Japan, South Korea, and increasingly India are expanding investments in advanced biopharmaceutical manufacturing. Government initiatives supporting biotechnology development, domestic manufacturing capabilities, and regenerative medicine programs are contributing to regional demand. Japan's regulatory framework for regenerative medicine has also encouraged investment in cell therapy infrastructure and manufacturing technologies.

Middle East and Africa

Investment remains concentrated in a limited number of biotechnology hubs, particularly Israel, Saudi Arabia, and the United Arab Emirates. Government-supported healthcare diversification programs and life-science investment strategies are creating opportunities for technology suppliers, although manufacturing capacity remains relatively limited compared with North America and Europe.

South America

Brazil represents the largest regional opportunity due to its healthcare infrastructure, research institutions, and biotechnology development initiatives. Adoption remains concentrated in research and clinical settings, with commercial manufacturing activity developing at a slower pace. Import dependence for specialized manufacturing equipment continues to influence procurement costs.

Competitive Landscape

The automated and closed cell therapy market exhibits characteristics of a technology-driven and regulation-sensitive industry. Competitive positioning depends not only on equipment capabilities but also on process integration, regulatory support, service infrastructure, software functionality, and manufacturing expertise. Buyers frequently evaluate suppliers based on their ability to reduce implementation risk and support long-term commercialization objectives.

Miltenyi Biotec, Lonza, Sartorius AG, and Thermo Fisher Scientific, Inc. have expanded investments in integrated manufacturing solutions that connect cell processing, analytics, software, and consumables. Their strategies reflect growing customer demand for standardized manufacturing environments capable of supporting both development and commercial operations.

Danaher Corporation, through its life sciences businesses, continues to strengthen process automation and bioprocessing capabilities. Merck KGaA and Terumo Corporation maintain strong positions in cell processing technologies, while Fresenius Kabi leverages broader biopharmaceutical manufacturing expertise.

Emerging participants such as Cellares Inc. are pursuing highly automated manufacturing models designed to reduce labor intensity and increase throughput. Meanwhile, BioSpherix, LLC and ThermoGenesis focus on specialized manufacturing and controlled-environment solutions that address specific workflow requirements.

Barriers to entry remain relatively high because suppliers must combine engineering expertise, regulatory understanding, bioprocessing knowledge, software integration capabilities, and long-term customer support. Qualification requirements and switching costs further strengthen relationships between established suppliers and commercial manufacturers.

Recent Developments

• April 2026: Thermo Fisher Scientific launched the Gibco CTS Compleo Fill and Finish System, an automated, functionally closed manufacturing platform that streamlines cell therapy formulation and filling while improving sterility, consistency, and scalability.

• March 2026: Green Elephant Biotech launched Archimedes One, a dynamic adherent bioreactor designed for automated, scalable cell therapy manufacturing, reducing manual processing complexity while supporting closed-system cultivation of sensitive adherent cell types.

• March 2026: Sartorius introduced the Eveo Cell Therapy Platform, an integrated automated manufacturing and quality-control solution enabling multi-parallel autologous cell therapy production, improving throughput, reducing costs, and supporting commercial-scale operations.

• August 2025: US WorldMeds completed the acquisition of Adaptimmune’s cell therapy assets, including TECELRA®, strengthening its advanced therapy portfolio and supporting continued commercialization and development of engineered T-cell therapies.

Regulatory and Policy Environment

Regulatory oversight continues to evolve alongside the maturation of the cell therapy industry. Authorities, including the U.S. Food and Drug Administration, the European Medicines Agency, and regulators in Japan, South Korea, and other jurisdictions, increasingly assess manufacturing controls as part of broader product evaluations. Process consistency, product characterization, traceability, and contamination control remain recurring areas of regulatory attention.

Closed manufacturing systems align with several regulatory objectives because they reduce environmental exposure, improve process documentation, and support standardized operating procedures. Digital manufacturing records and integrated monitoring systems can also strengthen data integrity and inspection readiness.

National biotechnology strategies are providing additional support through manufacturing incentives, research funding, translational medicine initiatives, and advanced therapeutics development programs. However, regulatory requirements continue to differ across jurisdictions, requiring suppliers and therapy developers to maintain region-specific compliance strategies.

Outlook and Strategic Implications

Manufacturing economics are expected to become a more influential determinant of commercial success during the 2026–2031 period. Clinical efficacy will remain essential, but reimbursement acceptance, patient access, and production scalability will increasingly depend on manufacturing performance. Automated closed systems are therefore likely to become a core component of commercialization strategies rather than a secondary operational consideration.

Several strategic implications emerge for industry participants:

• Therapy developers: Manufacturing design decisions made during clinical development will increasingly affect commercial viability.

• Technology suppliers: Demand is shifting toward integrated platforms rather than standalone equipment offerings.

• Investors: Manufacturing scalability is becoming an important indicator of long-term commercial potential.

• CDMOs and service providers: Capacity expansion will require greater automation to manage labor constraints and quality expectations.

• Regulators and policymakers: Manufacturing consistency and product accessibility will remain closely linked policy objectives.

The market's direction over the forecast period will depend largely on the industry's ability to reduce manufacturing complexity while preserving product quality and regulatory compliance. Suppliers capable of delivering scalable, validated, and economically efficient manufacturing environments are expected to occupy increasingly important positions within the broader cell therapy ecosystem.

Automated and Closed Cell Therapy Market Scope: